Frank Priou

4.2k total citations
63 papers, 1.1k citations indexed

About

Frank Priou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Frank Priou has authored 63 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 16 papers in Surgery. Recurrent topics in Frank Priou's work include Prostate Cancer Treatment and Research (26 papers), Cancer Treatment and Pharmacology (20 papers) and Cancer, Lipids, and Metabolism (10 papers). Frank Priou is often cited by papers focused on Prostate Cancer Treatment and Research (26 papers), Cancer Treatment and Pharmacology (20 papers) and Cancer, Lipids, and Metabolism (10 papers). Frank Priou collaborates with scholars based in France, United States and Germany. Frank Priou's co-authors include Stéphane Oudard, Gwénaëlle Gravis, Philippe Beuzeboc, Florence Joly, Stéphane Culine, Frédéric Rolland, Christine Théodore, Yacine Merrouche, Bruno Coudert and Jean‐Pierre Droz and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Urology.

In The Last Decade

Frank Priou

60 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank Priou France 15 621 563 250 246 219 63 1.1k
Marius Lund‐Iversen Norway 17 499 0.8× 523 0.9× 279 1.1× 162 0.7× 122 0.6× 60 1.0k
Breelyn A. Wilky United States 22 912 1.5× 977 1.7× 379 1.5× 191 0.8× 148 0.7× 101 1.7k
Tipu Nazeer United States 20 412 0.7× 579 1.0× 318 1.3× 175 0.7× 332 1.5× 70 1.4k
Damien Pouessel France 20 844 1.4× 790 1.4× 377 1.5× 239 1.0× 638 2.9× 120 1.8k
Stacey Stein United States 18 802 1.3× 387 0.7× 315 1.3× 327 1.3× 260 1.2× 74 1.4k
Jia‐Huei Tsai Taiwan 20 492 0.8× 337 0.6× 258 1.0× 136 0.6× 490 2.2× 54 1.2k
Junhun Cho South Korea 23 846 1.4× 371 0.7× 269 1.1× 209 0.8× 268 1.2× 106 1.5k
Patricia L. Kandalaft United States 13 511 0.8× 270 0.5× 187 0.7× 239 1.0× 99 0.5× 15 891
Helene Geddert Germany 26 552 0.9× 491 0.9× 666 2.7× 183 0.7× 485 2.2× 49 1.7k
Caterina Fumagalli Italy 22 679 1.1× 677 1.2× 342 1.4× 295 1.2× 141 0.6× 62 1.4k

Countries citing papers authored by Frank Priou

Since Specialization
Citations

This map shows the geographic impact of Frank Priou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Priou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Priou more than expected).

Fields of papers citing papers by Frank Priou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Priou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Priou. The network helps show where Frank Priou may publish in the future.

Co-authorship network of co-authors of Frank Priou

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Priou. A scholar is included among the top collaborators of Frank Priou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Priou. Frank Priou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dalban, Cécile, Stéphane Oudard, Christine Chevreau, et al.. (2023). Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial. European Urology Oncology. 7(4). 742–750. 1 indexed citations
2.
Campion, L., Valérie Seegers, Oana Cojocarasu, et al.. (2023). Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS. Journal of Clinical Medicine. 12(4). 1636–1636. 2 indexed citations
3.
Vjaters, Egils, Karim Fizazi, Nicholas D. James, et al.. (2022). Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 40(6_suppl). 90–90. 1 indexed citations
4.
Borchiellini, Delphine, Aline Guillot, Jean-Baptiste Paoli, et al.. (2021). TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 19(6). 501–509. 34 indexed citations
5.
Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations
6.
Bouché, Olivier, Axel Le Cesne, María Rios, et al.. (2018). EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. PLoS ONE. 13(9). e0204117–e0204117. 9 indexed citations
7.
8.
9.
10.
Escudier, Bernard, Sophie Abadie‐Lacourtoisie, Ellen Blanc, et al.. (2015). Efficacy of everolimus in poor risk patients: Result of the POORTOR study.. Journal of Clinical Oncology. 33(7_suppl). 488–488. 2 indexed citations
11.
Pouessel, Damien, Stéphane Oudard, Gwénaëlle Gravis, et al.. (2012). Cabazitaxel dans le cancer de la prostate métastatique résistant à la castration ayant progressé pendant ou après traitement par docétaxel : l'expérience française de l'essai TROPIC. Bulletin du Cancer. 99(7-8). 731–741. 12 indexed citations
12.
Trédan, Olivier, Isabelle Treilleux, Qing Wang, et al.. (2012). Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Targeted Oncology. 8(4). 243–251. 32 indexed citations
13.
Guiu, Séverine, Laure Favier, Isabelle Van Praagh, et al.. (2010). Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Annals of Oncology. 22(2). 321–328. 17 indexed citations
14.
Oudard, Stéphane, Gwénaëlle Gravis, Jean-­Marc Ferrero, et al.. (2010). Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study. British Journal of Urology. 106(7). 974–978. 76 indexed citations
15.
Joly, Florence, Nadine Houédé, Sabine Noal, et al.. (2009). Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. Clinical Genitourinary Cancer. 7(2). E28–E33. 41 indexed citations
16.
Joly, Florence, Emmanuel Sevin, Alain Lortholary, et al.. (2009). Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial. Gynecologic Oncology. 116(3). 312–316. 6 indexed citations
17.
18.
Bennouna, Jaafar, Hervé Perrier, B Paillot, et al.. (2005). ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’. British Journal of Cancer. 94(1). 69–73. 20 indexed citations
19.
Chinet-Charrot, P., Hugues Bourgeois, Alain Lortholary, et al.. (2005). Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial. Journal of Clinical Oncology. 23(16_suppl). 5043–5043.
20.
Escudier, Bernard, Jean‐Pierre Droz, Frédéric Rolland, et al.. (2002). Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.. PubMed. 168(3). 959–61. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marius Lund‐Iversen Breakdown of academic impact, for papers by Breelyn A. Wilky Breakdown of academic impact, for papers by Tipu Nazeer Breakdown of academic impact, for papers by Damien Pouessel Breakdown of academic impact, for papers by Stacey Stein Breakdown of academic impact, for papers by Jia‐Huei Tsai Breakdown of academic impact, for papers by Junhun Cho Breakdown of academic impact, for papers by Patricia L. Kandalaft Breakdown of academic impact, for papers by Helene Geddert Breakdown of academic impact, for papers by Caterina Fumagalli
Rankless by CCL
2026